Article in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Kana N MiyataDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.ORCID 0000-0001-6486-4666
Denise M SmithDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.
Michifumi YamashitaDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States.ORCID 0000-0001-6221-8900
Shimok KimDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.
F Andrea YearginDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.ORCID 0009-0008-8469-7031
Melisa BeganovicDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.
Shao-Ling ZhangDépartement de Médecine, Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montreal, Quebec, Canada.ORCID 0000-0002-5255-6970
John S D ChanDépartement de Médecine, Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Montreal, Quebec, Canada.ORCID 0000-0002-7137-454X
Jeffrey H MinerDivision of Nephrology, Washington University in St. Louis, St. Louis, Missouri, United States.ORCID 0000-0002-1510-8714
Daniel N LealDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Jian-Ping LiDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.
Jonathan BrunoDivision of Nephrology, Saint Louis University, St. Louis, Missouri, United States.
Funding
Innovative Approaches to Treating Alport SyndromeR01DK128660 · NIDDK · WASHINGTON UNIVERSITY · PI MINER, JEFFREY H · 2021 to 2025
$2.2M
Alport FoundationBander Foundation 2022-2024Canadian Government | CIHR | Institute of Nutrition, Metabolism and Diabetes (INMD) MOP-86450Canadian Government | CIHR | Institute of Nutrition, Metabolism and Diabetes (INMD) PJ9-179813Canadian Government | CIHR | Institute of Nutrition, Metabolism and Diabetes (INMD) PJ9-18014Canadian Government | CIHR | Institute of Nutrition, Metabolism and Diabetes (INMD) PJT-186199HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK128660NIDDK NIH HHS R01 DK128660SLU Research Scholar in Internal Medicine Grant Miyata 2022
6 · The paper itself
Abstract
Renin-angiotensin-aldosterone system inhibitors (RAASis) have been the most extensively studied treatment for Alport syndrome, demonstrating established benefits for renal function and survival in both animals and humans. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) slow chronic kidney disease progression, but their renoprotective mechanisms in nondiabetic glomerular diseases remain unclear. Here, we investigated whether combining dapagliflozin (an SGLT2i) with ramipril (an angiotensin-converting enzyme inhibitor) enhances kidney protection compared with ramipril alone in Col4α3 knockout (KO) mice, a murine model of Alport syndrome. Alport and wild-type (WT) mice (129S1/SvImJ) received dapagliflozin (1.5 mg/kg/day), ramipril (10 mg/kg/day), or both (D/R) via drinking water from 4 wk of age. Mice were studied until 10 wk of age (short-term,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dapagliflozin, in addition to ramipril, ameliorates kidney disease progression in mice with Alport syndrome. · full record | OpenQuestion